TITLE

Mometasone furoate nasal spray plus oxymetazoline nasal spray: Short-term efficacy and safety in seasonal allergic rhinitis

AUTHOR(S)
Meltzer, Eli O.; Bernstein, David I.; Prenner, Bruce M.; Berger, William E.; Shekar, Tulin; Teper, Ariel A.
PUB. DATE
March 2013
SOURCE
American Journal of Rhinology & Allergy;Mar/Apr2013, Vol. 27 Issue 2, p102
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Allergic rhinitis (AR) and associated congestion adversely affect patients' lives. The intranasal corticosteroid mometasone furoate nasal spray (MFNS) is effective for AR symptoms including nasal congestion, and the intranasal decongestant oxymetazoline (OXY) is effective against nasal congestion, but the combination has not been fully studied. This study was designed to assess the efficacy of the combination of MFNS and OXY for the relief of seasonal allergic rhinitis (SAR) symptoms. Methods: This phase 2 controlled clinical trial randomized adolescent and adult subjects (≥12 years; 2-year SAR) to MFNS q.d. (200 μg) + 3 sprays/nostril of OXY 0.05% (MFNS + OXY3); MFNS q.d. + 1 spray/nostril of OXY (MFNS + OXY1); MFNS q.d.; OXY b.i.d.; or placebo for 15 days, with 1-week follow-up. Coprimary end points were change from baseline in morning/evening (A.M./P.M.) instantaneous (NOW) total nasal symptom score (TNSS) over days 1-15 and AUC (AUC[0-4 hr]) change from baseline in day 1 congestion. Results: In 705 subjects, both combinations reduced A.M./P.M. NOW TNSS over days 1-15 significantly more than OXY b.i.d. or placebo (p ≤ 0.002). Mean standardized AUC(0-4 hr) day 1 congestion change from baseline was significantly greater in combination and OXY b.i.d. groups (MFNS + OXY3, -0.92; MFNS + OXY1, -0.80; OXY b.i.d., -1.06) versus placebo (-0.57) and MFNS q.d. (-0.63). Combinations and MFNS q.d. were significantly effective for A.M./P.M. NOW TNSS over each weekly period; OXY b.i.d. was superior to placebo in week 1. Adverse events (AEs) were few and similar across treatments; one MFNS q.d. and one placebo subject experienced a serious AE, with neither considered treatment related. Conclusion: Combining MFNS with OXY relieves SAR symptoms, including congestion, with faster onset of action than MFNS q.d. and better sustained efficacy than OXY b.i.d.
ACCESSION #
86447306

 

Related Articles

  • Fluticasone Furoate. McCormack, Paul L.; Scott, Lesley J. // Drugs;2007, Vol. 67 Issue 13, p1905 

    Fluticasone furoate nasal spray is a new topical intranasal corticosteroid with enhanced affinity for the glucocorticoid receptor and low systemic expo- sure, which was recently approved in the US for the treatment of seasonal or perennial allergic rhinitis in adults and in children aged...

  • PROFILE OF INTRANASAL CORTICOSTEROIDS IN ITALY: SAFETY, COST/EFFECTIVENESS, LOCAL AND SYSTEMIC ADVERSE EFFECTS. Marchese, Donatella; Gullo, Federico; Gallina, Salvatore; Speciale, Riccardo // Euromediterranean Biomedical Journal;01/01/2014, p102 

    Background: Allergic Rhinitis is a common and often debilitating disease that affect, nowadays, not only young people. For this reason an effective treatment is necessary to minimize the impact of allergic rhinitis in general population. Objective: The aim of this review is to inquire intranasal...

  • INTRANASAL BUDESONIDE OR FLUTICASONE FOR ALLERGIC RHINITIS. Yedavally-Yellayi, Sri Kala; French, Linda // Journal of Family Practice;Apr1999, Vol. 48 Issue 4, p248 

    The article cites a research study that analyzes which intranasal steroid, budesonide or fluticasone, is more effective in controlling symptoms of perennial allergic rhinitis. Allergic rhinitis affects from 10% to 30% of the population of the United States. Intranasal corticosteroids have become...

  • Mometasone Furoate Nasal Spray Relieves the Ocular Symptoms of Seasonal Allergic Rhinoconjunctivitis. Igarashi, Tsutomu; Nakazato, Yuri; Kunishige, Tomoyuki; Fujita, Miho; Yamada, Yumi; Fujimoto, Chiaki; Okubo, Kimihiro; Takahashi, Hiroshi // Journal of Nippon Medical School;2012, Vol. 79 Issue 3, p182 

    Background: Recent studies have examined the effects of intranasal corticosteroids (INSs) in relieving the ocular symptoms of seasonal allergic rhinoconjunctivitis (SAR) and perennial allergic rhinitis. However, because most of these studies were based on subjective assessments by patients, the...

  • Efficacy of mometasone furoate nasal spray for nasal symptoms, quality of life, rhinitis-disturbed sleep, and nasal nitric oxide in patients with perennial allergic rhinitis. Yamada, Takechiyo; Yamamoto, Hideyuki; Kubo, Seita; Sakashita, Masafumi; Tokunaga, Takahiro; Susuki, Dai; Narita, Norihiko; Ogi, Kazuhiro; Kanno, Masafumi; Yamashita, Shinji; Terasawa, Yuko; Sugano, Yuichiro; Masada, Mikio; Fujieda, Shigeharu // Allergy & Asthma Proceedings;Mar/Apr2012, Vol. 33 Issue 2, p9 

    Intranasal corticosteroid therapy has exhibited effectiveness for improving nasal symptoms and quality of life (QOL) scores associated with seasonal allergic rhinitis. We prospectively investigated the efficacy of mometasone furoate nasal spray (MFNS) for improving the total nasal symptom score,...

  • CLINICAL TRIAL DIGEST.  // Pulmonary Reviews;Mar2007, Vol. 12 Issue 3, p26 

    The article provides information on several clinical trials of treatments for various diseases. Intranasal ciclesonide or placebo will be given to adults and adolescents with at least two-year history of perennial allergic rhinitis. 220 children ages 2 to 14 with intermittent asthma were...

  • Mometasone Furoate: A Review of its Intranasal Use in Allergic Rhinitis. Onrust, S.V.; Lamb, H.M. // Drugs;Oct1998, Vol. 56 Issue 4, p725 

    Mometasone furoate is a synthetic corticosteroid which has been evaluated for intranasal use in the treatment of adults and children with allergic rhinitis. In several large, well-controlled clinical trials, mometasone furoate 200µg administered once daily as an aqueous intranasal spray was...

  • Twenty-four-hour duration of effect of intranasal corticosteroids for seasonal allergic rhinitis symptoms: Clinical evidence and relevance. DuBuske, Lawrence M. // American Journal of Rhinology & Allergy;Jul/Aug2012, Vol. 26 Issue 4, p287 

    Background: Seasonal allergic rhinitis (SAR) symptoms are often most severe and/or disruptive during overnight and morning hours, resulting in cognitive/performance impairments and reduced quality of life throughout the following day. Surveys of allergy patients and health care practitioners...

  • Ciclesonide Nasal Spray: In Allergic Rhinitis. Dhillon, Sohita; Wagstaff, Antona J. // Drugs;2008, Vol. 68 Issue 6, p875 

    â–´ Ciclesonide nasal spray delivers the corticosteroid ciclesonide as a hypotonic spray via a metered-dose manual pump.â–´ Systemic exposure to ciclesonide and its active metabolite desisobutyryl-ciclesonide is low after intranasal administration. High protein binding...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics